Concurrent neprilysin inhibition and renin-angiotensin system modulations prevented diabetic nephropathy
| dc.contributor.author | Gaikwad, Anil Bhanudas | |
| dc.date.accessioned | 2023-12-20T09:27:39Z | |
| dc.date.available | 2023-12-20T09:27:39Z | |
| dc.date.issued | 2019-03 | |
| dc.description.abstract | Renin-angiotensin system (RAS) and natriuretic peptides system (NPS) perturbations govern the development of diabetic nephropathy (DN). Hence, in search of a novel therapy against DN, present study targeted both, NPS and RAS simultaneously using a neprilysin inhibitor (NEPi) in combination with either angiotensin receptor blocker (ARB) or angiotensin-converting enzyme 2 (ACE2) activator. | en_US |
| dc.identifier.uri | https://www.sciencedirect.com/science/article/abs/pii/S0024320519301171 | |
| dc.identifier.uri | http://dspace.bits-pilani.ac.in:8080/xmlui/handle/123456789/13461 | |
| dc.language.iso | en | en_US |
| dc.publisher | Elsevier | en_US |
| dc.subject | Pharmacy | en_US |
| dc.subject | Diabetic nephropathy | en_US |
| dc.subject | Renin-angiotensin system (RAS) | en_US |
| dc.subject | Diabetic nephropathy (DN) | en_US |
| dc.title | Concurrent neprilysin inhibition and renin-angiotensin system modulations prevented diabetic nephropathy | en_US |
| dc.type | Article | en_US |
Files
License bundle
1 - 1 of 1
No Thumbnail Available
- Name:
- license.txt
- Size:
- 1.71 KB
- Format:
- Item-specific license agreed upon to submission
- Description: